C
Camp4 Therapeutics Corporation (CAMP)
NGM – Real Time Price. Currency in USD
4.50
+0.10 (2.27%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.50
+0.10 (2.27%)
At close: May 12, 2026, 4:00 PM EDT
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer |
| Dr. Leonard I. Zon M.D. | Founder & Chairman of Scientific Advisory Board |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Mr. Caleb Moore | Chief Business Operations Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | camp-20260507.htm |
| 2026-04-23 | DEFA14A | defa14a-2026annualmeeting.htm |
| 2026-04-23 | DEF 14A | camp-20260422.htm |
| 2026-03-24 | 8-K | camp-20260318.htm |
| 2026-03-05 | 8-K | camp-20260305.htm |
| 2026-01-09 | 8-K | camp-20260109.htm |
| 2025-12-23 | 8-K | camp-20251222.htm |
| 2025-12-18 | 8-K | camp-20251218.htm |
| 2025-11-10 | S-3 | camp4therapeutics-atmsx3.htm |
| 2025-11-06 | 10-Q | camp-20250930.htm |
| Mr. Joshua Mandel-Brehm | CEO, President & Director |
| Ms. Alla Sigova Ph.D. | Senior Vice President of Platform |
| Ms. Kelly Gold | Chief Financial Officer |
| Ms. Michelle Gates | Senior VP & Chief People Officer |